Lab Genomics Agrees to Pay $1.25 Million
The Fountain Valley clinical laboratory and its owner resolve False Claims Act kickback allegations involving marketer commissions.
Updated on Nov. 6, 2026 in Healthcare

Live Poll
Do you trust that your doctor's lab test recommendations are based only on your medical needs?
Lab Genomics LLC and owner Leena Dalal agreed to pay $1.25 million to resolve allegations they paid kickbacks to marketers for laboratory test referrals. The settlement resolves claims brought in a qui tam lawsuit filed by Sunil Wadhwa and Ken Newton.
Why it matters
The allegations center on commissions allegedly paid to induce marketers to arrange for or recommend laboratory test orders, a practice that federal law restricts in healthcare. The case follows similar resolutions involving Admera Health LLC and NEXT Bio-Research Services LLC.
The settlement totals $1,250,000 paid to the United States, of which $225,000 goes to relators Sunil Wadhwa and Ken Newton. The alleged commission payments to three independent contractor marketers spanned January 2020 through September 2022, and their total value is not disclosed.
The players
Lab Genomics LLC
A clinical laboratory based in Fountain Valley, California, that agreed to the settlement.
Leena Dalal
The owner of Lab Genomics LLC who agreed to the settlement alongside the company.
The details
Prosecutors allege Lab Genomics paid value- and volume-based commissions to marketers, and invoices were structured to mask those payments as flat fees. The settlement resolves certain allegations in a qui tam lawsuit brought in the Eastern District of California.
Timeline
January 2020 through September 2022: alleged commission payments to three marketers occurred.
November 6, 2026: the Justice Department announced the settlement.
Market Landscape
The settlement continues a line of federal False Claims Act actions against clinical laboratories, following earlier resolutions with Admera Health LLC and NEXT Bio-Research Services LLC over similar marketer-commission allegations. It signals sustained enforcement against per-referral compensation arrangements in the lab testing sector.
Patients who receive laboratory tests may see referrals driven by financial incentives scrutinized under federal law. Providers and ordering physicians face heightened attention to how laboratory test referrals are compensated.
The takeaway
Federal enforcement continues to target per-referral compensation in laboratory testing, making arrangements that tie payments to test volume a notable compliance risk for labs and their marketing partners.
Further reading
Explore more Healthcare coverage tied to federal enforcement in the lab testing industry.
Live Poll
Do you trust that your doctor's lab test recommendations are based only on your medical needs?






